New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Vyome Holdings, Inc.

HIND

Healthcare Biotechnology

Vyome Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $319,700.00, up 24.4% from fiscal 2024.

Revenue
+67.6%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.20 0.25 −17.24%
Market cap
$10.2M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
4/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Where the cash went Fiscal 2025, year to Dec 31, 2025

Free cash flow was −$3.7M: capital expenditures were more than operating cash flow. Cash rose by $4.9M. What is a cash flow statement?

Free cash flow
−$3.7M
Returned to shareholders
$0.00
Debt, net
$791.3K borrowed
Change in cash
+$4.9M over the period
Where the cash went, in millions of dollars
Operating cash flow−3.7
Free cash flow−3.7
Shares issued, net+7.9
Debt raised, net+0.8
Other0.0
Change in cash4.9
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, nine years
FY16FY17FY18FY19FY20FY21FY22FY23FY24
Operating cash flow−$19M−$31M−$29M−$23M−$8.6M−$15M−$22M−$17M−$0.6M
Capex$0.0B−$1M−$1.3M$0.0B$0.0B$0.0B$0.0B$0$0
Free cash flow−$20M−$32M−$31M−$23M−$8.9M−$16M−$22M−$17M−$0.6M

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
(10.48) (1.45) (11.39) (46.21) (63.15) (21.63) (23.68) (37.38) (34.76) (20.47)
Depreciation & Amortization
0.01 0.02 0.15 2.15 2.47 3.36 0.96 0.57 0.39 0.39
Non Cash Items (Other)
6.68 0.43 (1.59) 21.45 48.02 9.71 3.11 4.80 4.85 1.04
Accounts Receivable Change
— 0.56 0.13 0.68 (0.28) 1.22 0.59 3.35 (3.71) 0.12
Change in inventories
— 0.92 (0.46) (1.19) (0.37) (1.17) 0.01 (0.16) (0.59) (0.46)
Accounts Payable Change
— — — — — (0.03) (0.54) 0.07 0.62 —
Change in payables and accrued liability
0.17 (0.06) (3.46) 0.45 (1.28) (0.99) (2.98) (0.69) 2.00 1.29
Change in other assets and liabilities
(0.13) 0.45 (0.34) 0.77 (0.78) 0.96 (0.33) 0.01 0.58 (1.28)
Operating Cash Flow
(3.75) (0.61) (16.96) (21.90) (15.37) (8.55) (22.87) (29.43) (30.62) (19.37)
Capital expenditures
— 0.00 (0.01) (0.09) (0.35) (0.39) (0.19) (1.28) (1.04) (0.35)
Net Aquisitions
— — — — 2.21 (2.00) — — — —
Short Term Investments Change (Net)
— — — — — — 2.55 20.80 (20.81) 6.55
Investing cash flow
— 0.00 (0.01) (0.09) 1.86 (2.39) 2.36 19.52 (21.86) 6.20
Repayment/Issuance of Debt (Net)
0.79 0.67 — — (9.50) 10.46 (10.00) — — —
Equity Repurchase (Common, Net)
7.86 0.02 17.57 3.13 46.03 0.68 23.38 10.02 0.61 68.30
Equity Repurchase (Preffered, Net)
— — — — — — — — — 14.52
Other financial activities
— 0.03 — 21.87 (3.23) (0.06) 3.18 (0.03) 4.91 (0.03)
Financing cash flow
8.66 0.70 17.57 3.13 33.30 11.08 13.38 9.99 0.61 82.79
Exchange Rate Adjustment
(0.03) 0.00 — 0.00 0.03 (0.11) — — — —
Change in Cash
4.88 0.09 0.60 (18.86) 19.81 0.02 (7.13) 0.08 (51.87) 69.62
Beginning Cash
0.10 0.02 3.96 22.82 3.01 2.99 21.19 21.11 72.98 3.36
Ending Cash
4.98 0.10 4.56 3.96 22.82 3.01 14.06 21.19 21.11 72.98
Stock Based Compensation
6.58 0.18 0.77 2.09 12.23 1.32 2.98 4.69 3.24 0.56
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
0.04 0.39 (4.13) 0.71 (2.71) 0.01 (3.26) 2.58 (1.10) (0.33)
Investments Change (Net)
— — — — — — 2.55 20.80 (20.81) 6.55
Issuance/Purchase of Shares
7.86 0.02 17.57 3.13 46.03 0.68 23.38 10.02 0.61 82.82
Other line items
Revenue per Employee
0.02 0.01 0.28 0.28 0.29 5.65 0.10 0.09 0.07 0.31

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026